Welcome to our dedicated page for Brainstorm Cell Therapeutics I news (Ticker: BCLI), a resource for investors and traders seeking the latest updates and insights on Brainstorm Cell Therapeutics I stock.
BrainStorm Cell Therapeutics Inc. (BCLI) generates a steady flow of news centered on its NurOwn® autologous stem cell platform for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Company press releases highlight clinical milestones, regulatory interactions, financing developments, and scientific presentations that shape the outlook for its lead investigational therapy.
News coverage frequently focuses on clinical trial progress for NurOwn, including the completed Phase 3 ALS study and preparations for the Phase 3b ENDURANCE trial under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration. Updates describe FDA clearance to initiate the Phase 3b trial, submission of an IND amendment, listing of the study on ClinicalTrials.gov, and operational steps such as site activation and manufacturing readiness.
Investors and observers will also find data-driven announcements, such as survival results from BrainStorm’s Expanded Access Program in ALS and pharmacogenomic and biomarker analyses presented at scientific meetings. These releases detail how NurOwn-treated cohorts performed relative to published ALS survival estimates and discuss factors like the UNC13A genotype and cerebrospinal fluid biomarker pathways.
Additional news items cover regulatory and community developments, including the FDA’s consideration of a Citizen Petition requesting renewed review of NurOwn data, as well as BrainStorm’s engagement with the ALS community. Financial results and capital-raising activities are reported through quarterly earnings releases and 8-K filings, alongside information about promissory and convertible promissory notes.
Stock Titan’s BCLI news page aggregates these company-issued updates and related coverage, allowing readers to follow clinical, regulatory, scientific, and financing events that may influence BrainStorm’s development trajectory. For those tracking BCLI, this page offers a single location to review the latest disclosed information on NurOwn, ALS and MS programs, manufacturing partnerships, and listing status changes.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) received a refusal to file letter from the FDA concerning its New Biologics License Application (BLA) for NurOwn, aimed at treating ALS. The FDA suggested that BrainStorm could request a Type A meeting to discuss the refusal. CEO Chaim Lebovits expressed disappointment but reaffirmed commitment to NurOwn's advancement. Despite the Phase 3 trial not meeting its primary outcome, some participants showed beneficial effects, indicating potential for further investigation and dialogue with the FDA.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) will host a conference call on November 14, 2022, at 8:00 a.m. ET, to discuss its third-quarter financial results and corporate updates for the period ending September 30, 2022. The call will feature CEO Chaim Lebovits and key executives who will answer questions from participants. Interested individuals can submit questions by November 10, 2022, and join via phone or a live webcast. BrainStorm is known for developing stem cell therapies for neurodegenerative diseases and is actively involved in clinical trials for its NurOwn® technology.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) presented new post-hoc analyses from the NurOwn Phase 3 ALS trial at the NEALS meeting, highlighting a clinically meaningful treatment effect despite the ALSFRS-R floor effect. The analyses accounted for participants with low baseline scores, revealing a treatment advantage in those with less advanced ALS. NurOwn treatment showed a nominally significant clinical response compared to placebo in pre-specified subgroups. These findings, alongside biomarker data indicating consistent treatment effects, bolster confidence in NurOwn's potential for ALS therapy.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced positive results from their NurOwn Phase 2 clinical trial on neuroprotective biomarkers in progressive multiple sclerosis (MS). An abstract titled 'NurOwn (MSC-NTF) Phase 2 Clinical Trial in Progressive MS' will be presented at the 38th Congress of the European Committee for Treatment and Research in MS from October 26-28, 2022, in Amsterdam. The treatment showed robust increases in cerebrospinal fluid neuroprotective biomarkers, supporting the proposed mechanism of action and clinical outcomes.
BrainStorm Cell Therapeutics Inc. (BCLI) presented new biomarker analyses for NurOwn® at the 5th Annual ALS ONE Research Symposium, highlighting its efficacy in treating amyotrophic lateral sclerosis (ALS). The study indicates that NurOwn affects biomarkers related to neuroinflammation and neurodegeneration across varying disease progression levels. The data reveals a significant treatment effect in less advanced ALS patients, with a preserved functional score of 2 points over 28 weeks compared to placebo. These findings support the need for considering floor effects in clinical endpoint evaluations.
BrainStorm Cell Therapeutics (BCLI) announced the peer-reviewed publication of Phase 2 trial results for its treatment NurOwn in progressive multiple sclerosis (MS) in the Multiple Sclerosis Journal. The study, which included 20 participants, demonstrated NurOwn's safety and showed preliminary efficacy, with 19% of treated patients meeting responder criteria. Key endpoints exhibited significant improvements compared to matched control patients from the CLIMB registry. No major adverse events were reported, confirming NurOwn's favorable safety profile.
BrainStorm Cell Therapeutics (BCLI) has announced plans to submit a Biologics License Application (BLA) to the FDA for NurOwn®, a stem cell therapy aimed at treating amyotrophic lateral sclerosis (ALS). This decision follows new clinical analyses that reinforce the efficacy conclusions from the Phase 3 trial. Financial results for Q2 2022 reveal a net loss of $7.0 million, up from $6.3 million the previous year, with cash reserves decreasing to $12.2 million. The company emphasizes the significance of the upcoming regulatory submission and expresses gratitude towards the ALS community and investors.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) will hold a conference call on August 15, 2022, at 8:00 a.m. Eastern Time to discuss financial results for Q2 2022, ending June 30, 2022. The call will feature CEO Chaim Lebovits, along with other executives, providing a corporate update and answering shareholder questions. Participants can submit questions by August 11, 2022, and access the call by dialing specified numbers or via a webcast. BrainStorm focuses on innovative therapies for neurodegenerative diseases.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced significant presentations at upcoming ALS and MS conferences in June 2022. Key findings from the ALS Phase 3 trial will be shared at the ENCALS meeting in Edinburgh, emphasizing the importance of addressing floor effects in ALSFRS-R outcomes. At the CMSC meeting in Maryland, three posters will discuss the effects of NurOwn therapy on visual outcomes and biomarkers in progressive MS. These insights aim to enhance understanding of NurOwn's potential benefits for patients with neurodegenerative diseases.
BrainStorm Cell Therapeutics Inc. (BCLI) announced financial results for Q1 2022, reporting a net loss of $5.4 million, down from $6.7 million in Q1 2021. Cash and equivalents decreased to $18.4 million from $22.1 million at the end of 2021. The company is enhancing its leadership team with new appointments, focusing on the advancement of its ALS treatment, NurOwn®. Promising Phase 3 data has been shared, indicating significant effects on ALS biomarkers. BrainStorm continues to engage with ALS experts and plans to present at upcoming conferences.